TransOral Pharmaceuticals, a Pt. Richmond, Calif. developer of a drug that treats insomnia, has raised $40 million in a fourth round of funding.

See the company’s announcement here.

The investor syndicate was led by New Enterprise Associates (NEA) and included follow-on investments by New Leaf Venture Partners, Montreux Equity Partners, InterWest Partners, Hamilton BioVentures, Vivo Ventures, Peninsula Equity Partners, and Hercules Technology Growth Capital.